Therefore, our results showed that dual IFNβ- and sTRAIL-modified MSCs may provide high therapeutic efficacy by either direct cell killing or indirect antitumor immunity, suggesting that the use of MSCs for tumor-specific gene therapy is a potential therapeutic strategy for cancer treatment. The gene discussed is IFNB1; the disease is cancer.